Therapeutics Granted Orphan Drug Designation by the FDA for Autoimmune Hepatitis

[In The News]

STOCKHOLM, Feb. 5, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis (AIH). More information about the ODD...

View the full article